Vera Therapeutics, Inc. Class A Common Stock
Here’s whether Vera Therapeutics, Inc. Class A Common Stock (VERA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 39 — healthy momentum range; strong 1-year return of +48.7%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.61% over 10 days); 3-month momentum negative (-15.2%). Currently 43.6% off its 52-week high. Score: -3/7.
VERA is trading below its 200-day MA ($38.98) — a key warning sign the longer-term trend is under pressure. An RSI of 39.1 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +48.7% compares to +20.4% for SPY (beat the market by 28.3%). The current 43.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.